Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Creators
- Holmes Frankie A1
- Moy Beverly2
-
Delaloge Suzette3
- Chia Stephen KL4
- Ejlertsen Bent5
-
Mansi Janine6
-
Iwata Hiroji7
- Gnant Michael8
-
Buyse Marc9
- Barrios Carlos H10
- Silovski Tajana11
-
Šeparović Robert12
- Bashford Anna13
- Zotano Guerrero Angel14
- Dendeluri Neelima15
- Patt Debra16
- Gokmen Erhan17
- Gore Ira18
- Smith II John W19
- Loibl Sibylle20
- Masuda Norikazu21
- Tomašević Zorica22
- Petrakova Katarina23
- DiPrimeo Daniel24
- Wong Alvin25
- Martin Miguel25
- Chan Arlene26
- ExteNET Study Group
- 1. a Texas Oncology, P.A., US Oncology Research, Houston, TX, USA
- 2. Massachusetts General Hospital Cancer Center, Boston, MA, USA
- 3. Institut Gustave Roussy, Villejuif, France
- 4. BC Cancer Agency, Vancouver, BC, Canada
- 5. Rigshospitalet, Copenhagen, Denmark
- 6. Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom
- 7. Aichi Cancer Center, Chikusa-ku, Nagoya, Japan
- 8. Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
- 9. International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium
- 10. Hospital Sa˜o Lucas, PUCRS, Porto Alegre, Brazil
- 11. Department of Oncology, UHC Zagreb, Zagreb, Croatia
- 12. University Hospital for Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia
- 13. Auckland Hospital, Auckland, New Zealand
- 14. Instituto Valenciano de Oncologia, Valencia, Spain
- 15. Virginia Cancer Specialists, US Oncology Research, Arlington, VA, USA
- 16. Texas Oncology e Round Rock, US Oncology Research, Austin, TX, USA
- 17. Ege University Faculty of Medicine, Izmir, Turkey
- 18. Alabama Oncology, Birmingham, AL, USA
- 19. Northwest Cancer Specialists, P.C., US Oncology Research, Vancouver, VA, USA
- 20. Center for Hematology and Oncology Bethanien, Frankfurt, Germany and German Breast Group, Neu-Isenburg, Germany
- 21. Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 22. Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
- 23. Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 24. Puma Biotechnology Inc., Los Angeles, CA, USA
- 25. Instituto de Investigacio´n Sanitaria Gregorio Maran˜o´n, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
- 26. Breast Cancer Research Centre-WA & Curtin University, Perth, Australia
Description
Abstract. Background: ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved invasive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET. Methods: In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1e3c (amended to stage 2e3c) HER2-positive breast
cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab were eligible. Patients were randomly assigned to oral neratinib 240 mg/day or placebo for 1 year. Randomisation was stratified according to hormone receptor (HR) status (HR-positive vs. HR-negative), nodal status (0, 1e3 or 4þ), and trastuzumab regimen (sequentially vs. concurrently with chemotherapy). Overall survival was analysed by intention to treat. ExteNET is registered (Clinicaltrials.gov: NCT00878709) and is complete.
Results: Between July 9, 2009, and October 24, 2011, 2840 women received neratinib (n Z 1420) or placebo (n Z 1420). After a median follow-up of 8.1 (IQR, 7.0e8.8) years, 127 patients (8.9%) in the neratinib group and 137 patients (9.6%) in the placebo group in the intention-to-treat population had died. Eight-year overall survival rates were 90.1% (95% CI 88.3e91.6) with neratinib and 90.2% (95% CI 88.4e91.7) with placebo (stratified hazard ratio 0.95; 95% CI 0.75e1.21; p Z 0.6914).
Conclusions: Overall survival in the extended adjuvant setting was comparable for neratinib and placebo after a median follow-up of 8.1 years in women with early-stage HER2- positive breast cancer.
Notes
Files
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer ...2023.pdf
Files
(1.9 MB)
Name | Size | Download all |
---|---|---|
md5:6b95a9592623eaeb39b3b5f54312d27f
|
1.9 MB | Preview Download |
Additional details
Related works
- Is documented by
- 36898233 (PMID)
- Is part of
- 0959-8049 (ISSN)
- Is supplemented by
- 10.1016/j.ejca.2023.02.002. (DOI)